© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Liquid Biopsies
FoundationOne Liquid CDx Granted New and Expanded FDA Indications in Various Solid Tumors
October 28, 2020
The FDA has granted approval to the FoundationOne Liquid CDx as a companion diagnostic indicated for the to identify patients who may derive benefit from treatment with 3 FDA-approved targeted therapies, including alpelisib, rucaparib, and alectinib.
FDA Approves Liquid Biopsy Companion Diagnostic for Multiple Indications
August 27, 2020
The FDA has granted approval to FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for all solid tumors with multiple companion diagnostic indications.
What’s Driving, and Blocking the Liquid Biopsy Evolution in Non–Small Cell Lung Cancer?
August 20, 2020
The application of liquid biopsies is becoming more common in the field of non–small cell lung cancer as the utility of liquid biopsies in the detection of key biomarkers continues to be confirmed through clinical trials.
Bladder EpiCheck Demonstrates Accuracy for Detection of Urothelial Carcinoma Recurrence
July 20, 2020
“Accurately identifying patients with high-grade UTUC is critical, as the disease progression can be deadly and the standard treatment – removal of ureter and kidney – leads to major morbidity."
Positive Tepotinib Data Underscore Value of Liquid Biopsies in Non-Small Cell Lung Cancer
July 01, 2020
In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discussed the results of the phase II VISION study, which evaluated tepotinib in patients with advanced non-small cell lung cancer and harbor the MET exon 14 skipping mutation. She also highlighted the role of liquid biopsy in this space.
Three Comprehensive Liquid Biopsy Tests Launched for Use in Patients With Cancer
June 30, 2020
"The launch of these 3 liquid biopsy assays exemplifies our commitment to providing the most comprehensive oncology menu for our clients as a one-stop-shop for their testing needs."
Hitting the Target: Rapid Evolution of Plasma Assays Continues to Move Genomic Profiling Toward More Efficient Testing Methods
May 20, 2020
"Liquid biopsy is useful at any time when a physician needs genomic information about their patient’s cancer in order to make a treatment decision."
Microfluidic Platforms Help Isolate Rare Cells in Leukemias
May 17, 2020
In an interview with Targeted Oncology, Steve A. Soper, PhD, discussed microfluidic platforms for use in isolating circulating leukemia cells and plasma cells in patients with acute lymphoblastic leukemia and acute myeloid leukemia.
Liquid Biopsy Assay Detects 50+ Types of Cancer and Identifies Cancer Origin in Tissue
April 06, 2020
The first liquid biopsy assay, a blood test, to detect over 50 types of cancer has been developed and is able to identify in which part of the body that the cancer originated in, based on findings from a prospective multicenter case-control observational trial, the CCGA study published in Annals of Oncology. The test also identified cancer prior to symptoms in most patients, according to a press release.
Investigators Gain Actionable Information Without Tumor Tissue
March 31, 2020
Use of the liquid biopsy assay MSK-ACCESS has led to detection of actionable genetic variants in 40% of tumor samples, offering an attrac­tive alternative to invasive tumor biopsies in patients with no available tissue for testing.